ARA290 Protects Kidneys from Cisplatin Chemotherapy Damage by Modulating Inflammation

Cisplatin is a potent chemotherapy drug widely used against various cancers, but its clinical utility is often limited by severe side effects, particularly cisplatin-induced nephrotoxicity (kidney damage). This toxicity is primarily driven by oxidative stress, inflammation, and apoptosis (programmed cell death) in kidney cells. Current strategies to mitigate this damage are often insufficient, highlighting an urgent need for novel therapeutic interventions. This study specifically addresses the knowledge gap regarding the protective mechanisms of ARA290, a specific ligand for the erythropoietin/CD131 heteroreceptor, against cisplatin-induced kidney injury by exploring its impact on apoptotic and inflammatory pathways.

Treatment with ARA290 significantly attenuated the markers of kidney injury induced by cisplatin. Serum creatinine levels, a key indicator of kidney function, were reduced by 43% in the ARA290-treated group compared to the cisplatin-only group (p<0.01). Histopathological analysis revealed a 70% decrease in tubular necrosis and inflammatory cell infiltration in the kidneys of animals receiving ARA290. Molecular investigations showed that ARA290 significantly modulated key pathways: > ARA290 treatment led to a 65% reduction in caspase-3 activity (a marker of apoptosis) and a 58% decrease in TNF-α (a pro-inflammatory cytokine) expression compared to the cisplatin group (p<0.001 for both). Furthermore, ARA290 increased the expression of anti-apoptotic protein Bcl-2 by 2.5-fold and anti-inflammatory cytokine IL-10 by 1.8-fold.